Chemotherapy-induced peripheral neuropathy Book Section
| Authors: | Custodio, C. M.; Knowlton, S. E. |
| Editors: | Frontera, W. R.; Silver, J. K.; Rizzo, T.D. Jr |
| Article/Chapter Title: | Chemotherapy-induced peripheral neuropathy |
| Abstract: | Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent complication and dose-limiting side effect of cancer treatments, stemming from damage to the peripheral nervous system as a result of neurotoxic agents. Common medications that cause CIPN include platinum agents, vinca alkaloids, taxanes, and bortezomib, among others. Symptoms depend on the type of chemotherapy agent used, total dose, frequency, and duration in addition to patient-specific comorbidities. Sensory nerve fibers are more commonly affected, but motor and autonomic nerve fibers can also be involved. Patients can present with pain, numbness, paresthesias, and dysesthesias in a distal symmetric distribution. Electrodiagnostic studies can determine the type of nerve fiber pathophysiology as either demyelinating or axonal, and may also define the severity of damage. While there are no preventative agents for CIPN, symptomatic treatment of CIPN is possible with neuropathic pain agents, antidepressants, and other pharmacologic and nonpharmacologic treatments. Rehabilitative efforts can work on impairments including weakness, reduced proprioception, and poor balance and gait. While research is limited on procedures, trials of neurostimulation may be helpful. CIPN is a challenging medical condition, but can be treated with a comprehensive management plan. © 2020 Elsevier Inc. All rights reserved. |
| Keywords: | chemotherapy; peripheral neuropathy; neuropathic pain; taxanes; vinca alkaloids; platinum agents |
| Book Title: | Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain, and Rehabilitation. 4th ed |
| ISBN: | 978-0-323-54947-9 |
| Publisher: | Elsevier Inc. |
| Publication Place: | Philadelphia, PA |
| Date Published: | 2018-09-26 |
| Start Page: | 529 |
| End Page: | 532 |
| Language: | English |
| DOI: | 10.1016/b978-0-323-54947-9.00097-3 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 97, part of "Part 2: Pain" -- Export Date: 1 March 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work